SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2015

Forward Pharma A/S

Østergade 24A, 1
1100 Copenhagen K, Denmark

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).

Yes o No x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).

Yes o No x

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

Regulation FD Disclosure

A copy of the intellectual property review and update of Forward Pharma A/S is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

The information contained in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

FORWARD PHARMA A/S

Date: April 23, 2015

By: /s/ Joel Sendek
Joel Sendek
Chief Financial Officer

FORWARD PHARMA

FP187: Intellectual Property Review

April 23, 2015

Forward-Looking Statements

This presentation contains forward-looking statements about Forward Pharma A/S based on management's current expectations, which are subject to known and unknown uncertainties and risks. Our actual results could differ materially from those discussed due to a number of factors, including, but not limited to, our ability to raise additional financing on favorable terms, the success of our clinical trials, our ability to obtain regulatory approval of FP187, our success in maintaining and defending our patent estate and other risk factors included in our filings with the U.S. Securities and Exchange Commission. We are providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise.

This presentation is not intended to be a source of legal advice.

Agenda

- **FWP Introduction**	Joel Sendek
- **IP Overview**	Brian Slater
- **Interference Background**	Judge Stoner (Ret.)
- **FWP Interference**	Brian Slater
- **Q & A**	All

Speakers

Joel Sendek:

CFO of FWP since August 2014; 25 years in life-sciences sector, including 17 as a Senior Biotechnology Analyst

Brian Slater:

Partner and Chair of the Life Sciences practice at Kramer Levin; over 20 years experience in patent litigation

Judge Stoner (Ret.):

Patent Attorney at Greenblum and Bernstein, P.L.C. for over 10 years; USPTO Administrative Patent Judge for 17 years, including 8 years as Chief Judge

FWP Introduction

FWP – The Investment Opportunity



Introduction to Forward Pharma

- Focused on DMF since 2004
- FP187: Proprietary slow release formulation of DMF
- 480 mg daily dose in MS patent application allowable and '871 patent interference declared
- MS NDA-enabling Phase 3 trial: 1 trial, 1 year endpoint
- IPO priced 10/14/2014, raised $235 M in gross proceeds
- Well capitalized to pursue patent and development strategies

FP187 Clinical Differentiation

- Same active pharmaceutical ingredient as Tecfidera® but new formulation may improve tolerability
- FP187 utilizes an “erosion matrix”

Formulation Differentiation



Financial Position

Well capitalized following IPO with an efficient business model

Balance Sheet ($)	12/31/14
Cash and Cash Equivalents	$223.5 M

Income Statement ($ in thousands)	Year Ended 2014
R&D Expenses	$10,547
G&A Expenses	9,154
Operating Loss	$19,701

BIIB to FWP Current Relative Valuation

* As of 4/22/15

**Leerink estimates 2013 – 2028

IP Overview

Core Composition Patent Family

- Based on international application filed on October 7, 2005
- Includes the use of 480 mg of DMF per day to treat multiple sclerosis ("MS")

USPTO and EPO Claims Covering 480 mg/day

6 separate patent applications with claims to 480 mg/day with the same priority date of October 7, 2005

	Application Number	Description
US	11/576,871	Treating MS with DMF at 480 mg/day *** Interference declared; FWP as Senior Party – 4/13/15**
US	14/213,399	Up-titration of DMF to 480 mg/day doses for the treatment of MS
US	14/212,503	Treating MS with DMF at 480 mg/day to reach certain MMF levels in the bloodstream
European	EP14172398.1	Treating MS with 480 mg/day of DMF wherein the pH controlled release compositions have an enteric coat *** Intention to grant – 3/30/15**
European	EP14172396.5	Treating MS with 480 mg/day of controlled release DMF
European	EP14172390.8	Treating MS with 480 mg/day of controlled release DMF with particular in vitro dissolution profile

German Utility Model

- Forward Pharma filed a lawsuit against BIIB on November 18, 2014
- Alleges infringement by Biogen's marketing of Tecfidera® in Germany with a label instructing a daily dose of 480 mg for MS
- An oral proceeding is scheduled for February 16, 2016 at the Regional Court in Dusseldorf

EP2316430 ('430) Patent

- Granted patent that covers DMF formulations (including FP187) with certain dissolution profiles
- An oral hearing has been scheduled for June 24th and 25th, 2015 at the EPO

Forward Pharma Detailed Timeline: 2004-2008

FP187 core composition patents filed at least 1 year, 4 months, 1 day earlier



Erosion Matrix Patent Family

- Based on international application PCT/EP2010/050172, filed in 2010
- Covers our delayed and slow release formulations of DMF in FP187
- EP2379063 (covering matrix formulations with a thin enteric coating) has been granted by the EPO. Multiple third parties, including Biogen, are opposing this patent
- U.S. Patent No 8,906,420 ("Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix") issued on December 9, 2014; expires January 2030

Interference Background

Interference Procedure

- Administrative proceeding at the USPTO to determine who was first to invent
- Senior Party versus Junior Party
  - Senior Party: Has the earliest effective filing date to the invention; entitled presumption that it invented first
  - Junior Party: Has the burden of proof to show a date of invention that predates our invention
- Each party can dispute the patentability of the other party's claims, challenge the senior party designation and present proof of dates of invention prior to the effective filing date

Interference Considerations

- Reduction to practice
- Conception
- Diligence

Interference Process

Motions Phase (~1 yr)

Three-judge panel at PTAB decides any patentability and senior party issues

Priority Phase (~1 yr)

Three-judge panel gives final judgment on priority

Resolution

Resolution

Average Time to Resolution: 13 months, excluding appeals

FWP Interference

Interference No. 106,023

- On April 13, 2015 the Patent Trial and Appeal Board (PTAB) declared an interference between Forward Pharma and Biogen regarding the treatment of multiple sclerosis with a 480 mg daily dose of DMF
- Forward Pharma designated as the “Senior Party” based on earlier patent filing
- If we prevail, our '871 patent application will issue and Biogen’s '514 patent will be cancelled

Senior vs. Junior Party

- **Forward Pharma: "Senior Party"**
  Has the earliest effective filing date to the invention; entitled presumption that it invented first

- **Biogen: "Junior Party"**
  Has the burden of proof to show a date of invention that predates our invention

USPTO asked that at the initial conference call, "Biogen should be prepared to discuss how it expects to prevail in the interference."

Priority Dates Designated by the USPTO

- **Forward Pharma:** October 8, 2004 and October 7, 2005
- **Biogen:** February 8, 2007, February 7, 2008 and January 13, 2011

480 mg/day for MS: Forward Pharma '871 and Biogen '514

Forward Pharma US '871

- A method of treating…multiple sclerosis comprising orally administering …(a) a therapeutically effective amount of dimethyl fumarate…wherein the therapeutically effective amount…is **480 mg per day**
- **Latest filing date: 10/07/05**

Biogen US '514

- A method of treating…multiple sclerosis comprising orally administering…a therapeutically effective amount of dimethyl fumarate…about **480 mg per day**
- **Earliest filing date: 02/08/07**

The Count Provided by the PTAB

A method of treating a human in need of treatment for multiple sclerosis comprising orally administering to the human a pharmaceutical composition consisting essentially of (a) a therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof, and (b) one or more pharmaceutically acceptable excipients, wherein the therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof is about 480 mg per day.

Schedule for the Interference

- May 22, 2015: Each party files and serves a list of motions the party intends to file
- May 29, 2015: Initial conference call to discuss the interference
- July 10, 2015: File authorized motions and file priority statements
- July 31, 2015: File authorized responsive motions
- September 11, 2015: File oppositions to all motions
- October 23, 2015: File all replies
- November 23, 2015: File request for oral argument, motions to exclude and observations
- December 21, 2015: File oppositions to motions to exclude evidence and file response to observations
- January 9, 2016: File replies to oppositions to motions to exclude
- January 16, 2016: File exhibits and sets of motions
- January 22, 2016: Default oral argument

Provisional Rights

Potential royalty initiation date

- Forward's '871 claims published on April 10, 2014
- Biogen was provided a copy of Forward's published claims on September 8, 2014

Reasonable Royalty

- Patentee who wins infringement case is entitled to no less than a "reasonable royalty"
- Legal framework:
  - Hypothetical negotiation between willing licensor and willing licensee on the eve of infringement
    - What is the maximum the infringer would pay the patentee to be able to stay on the market
    - What is the minimum the patentee would accept to allow accused product to stay on the market
- **Analysis assumes: patent is valid and infringed**

Reasonable Royalty "Factors"

Factors that are relevant to a reasonable royalty include:

- Whether infringer and patentee are competitors
- Whether infringer's sales deplete patentee's market potential
- The established profitability of the product, its commercial success and current popularity
- The utility and advantages of the patent property over old modes or devices
- Prospects for a non-infringing alternative
- Importance of the patent for the success of the product

Royalty Regimes

	Academic Inventor	Industrial Inventor
Competitive Product	NO	YES
Active R&D Spend	NO	YES
Ability to Commercialize	NO	YES
Opportunity Cost	LOW	HIGH
Royalty	LOW	HIGH
Example	Cabilly	Late-stage Biotech Deals

Potential FP187 Patent Protection in the US



Potential FP187 Patent Protection in Europe



Corporate Overview

Management

- **Peder M. Andersen, MD**
  Chief Executive Officer & Chief Operating Officer
  - More than 25 years experience in the pharmaceutical industry
  - Several years experience in business development experience, both generic and proprietary in Europe
- **Joel Sendek**
  Chief Financial Officer
  - 18 years as a sell-side analyst, most recently as Managing Director, Healthcare Equity Research, Stifel Financial Corp.
  - Former Head of Business Development, Progenics
  - Corporate Finance, Goldman Sachs

Board of Directors

- **Florian Schönharting**
  NB Capital
- **J. Kevin Buchi**
  Tetralogic, previously Teva, Cephalon
- **Torsten Goesch, MD, PhD**
  Rosetta Capital
- **Jan G. J. van de Winkel, PhD**
  Genmab

Scientific Advisors

- **Fred Lublin, MD**
  Mount Sinai Hospital
- **Giancarlo Comi, MD**
  Hospital San Raffaela, Milan
- **Kristian Reich, MD**
  Dermatologikum Hamburg
- **Jerry Wolinsky, MD**
  University of Texas, Medical School
- **Per Soelberg Sørensen, MD**
  Rigshospitalet, Copenhagen University Hospital
- **Ulrich Mrowietz, MD**
  Psoriasis-Center Kiel

Select Investors

- **Nordic Biotech**
- **BioScience Managers Limited**
- **The Baupost Group**
- **BVF Partners LP**

IP Key Upcoming Events

- June 24/25th, 2015 — '430 Patent Application: Oral hearing at EPO
- July 10, 2015 — '871 Interference: File authorized motions and priority statements
- Mid-2015 — '8.1 EU Patent Application: Possible grant
- September 11, 2015 — '871 Interference: File oppositions to motions
- January 22, 2016 — '871 Interference: Default oral argument
- February 16, 2016 — German Utility Model: Oral proceeding scheduled

Summary

- Focused on DMF since 2004
- FP187: Proprietary formulation of DMF
- 480 mg daily dose in MS patent application allowable and '871 patent interference declared
- MS NDA-enabling Phase 3 trial: 1 trial, 1 year endpoint
- Well capitalized with over $200 million in cash

Q & A

Appendix

Core Composition Patent Family

- Based on international application PCT/DK2005/000648, filed on October 7, 2005
- Includes the use of 480 mg of DMF per day to treat multiple sclerosis ("MS")
- Any patents issued from patent applications in our Core Composition Patent family based on PCT/DK2005/00648 will expire on October 7, 2025 at the latest, subject to patent term adjustments in the U.S.

11/576,871 Patent Application

- Claims the use of 480 mg of DMF per day as a treatment for MS
- On April 13, 2015, an administrative patent judge at the U.S. Patent Trial and Appeal Board (PTAB) declared an interference against Biogen's U.S. patent No. 8,399,514
- Forward Pharma designated "senior party"

14/213,399 Patent Application

- Claims the use of delayed release formulations of DMF to treat MS according to an up-titration (i.e., increasing dose) regimen that reaches a total daily dose of 480 mg
- On April 1, 2015, a USPTO patent examiner issued a “final rejection,” but may ultimately find our '399 application to be allowable
- These claims are substantially the same as the respective claims in another application No. 13/957,117 which were found allowable but we elected to abandon those claims

14/212,503 Patent Application

- Claims a method of treating a MS subject with 480 mg of DMF per day, using delayed release formulations containing from 120 mg to 240 mg of DMF which, following administration, result in certain levels of MMF in the bloodstream
- On April 17, 2015, a USPTO patent examiner issued a “final rejection” on this patent application but may ultimately find our '503 application to be allowable
- These claims are substantially the same as the respective claims in another application No. 13/957,220 which were found allowable but we elected to abandon those claims

EP14172398.1 ('8.1) Patent Application

- Covers, among other things, the treatment of MS with 480 mg per day of DMF wherein the pH controlled release compositions have an enteric coat
- The EPO has issued a communication of intention to grant a patent regarding this patent application
- The EPO examiner allowed our 480 mg patent claims after considering two third-party observations requesting (1) that no claims be granted and (2) that the examination be suspended
- This patent will be our first issued patent covering the use of 480 mg per day of DMF in MS, but could be opposed in the EPO within 9 months of grant
- This patent, if granted, will expire in October 2025

EP141723396.5 ('6.5) Patent Application

- Covers, among other things, the treatment of MS with 480 mg per day of DMF using a controlled release composition
- The EPO has completed its initial review of this application and has issued a negative search report; novelty has been acknowledged and only objections to the inventive step have been raised
- We expect a response to be filed on or before April 24, 2015

EP14172390.8 ('0.8) Patent Application

- Covers, among other things, the treatment of MS with 480 mg per day of DMF using a controlled release composition with a particular in vitro dissolution profile
- The EPO has completed its initial review of this application and has issued a positive “European search report” indicating that the application meets patentability requirements
- Two third party observations have since been filed on behalf of unidentified parties
- We are in the process of responding to the third party observations

German Utility Model DE202005022112.0

- On November 18, 2014, Forward Pharma filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd. in the Regional Court in Dusseldorf
- Alleges infringement by Biogen's marketing of Tecfidera® in Germany with a label instructing a daily dose of 480 mg for MS
- Forward seeks damages for Biogen sales of Tecfidera® in Germany
- An oral proceeding is scheduled for February 16, 2016 at the Regional Court in Dusseldorf
- Forward's Utility Model published June 5, 2014 and expires October 7, 2015

EP2316430 ('430) Patent

- Granted patent that covers DMF formulations (including FP187) with certain dissolution profiles
- Multiple third parties, including Biogen, are opposing our '430 patent before the EPO
- On December 17, 2014 the opposition division of the EPO delivered a preliminary, non-binding opinion rejecting all grounds of opposition except lack of novelty regarding our '430 patent
- An oral hearing has been scheduled for June 24th and 25th, 2015 at the EPO